Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Randomized, Multicenter, Two-Arms Efficacy and Safety Study of 14 Days Treatment With Finafloxacin 400 mg b.i.d. Plus Amoxicillin 1000 mg b.i.d.Versus Finafloxacin 400 mg b.i.d. Plus Esomeprazole 40 mg b.i.d. in Patients With Helicobacter Pylori Infection.

Next Previous
Trial Profile

An Open-Label, Randomized, Multicenter, Two-Arms Efficacy and Safety Study of 14 Days Treatment With Finafloxacin 400 mg b.i.d. Plus Amoxicillin 1000 mg b.i.d.Versus Finafloxacin 400 mg b.i.d. Plus Esomeprazole 40 mg b.i.d. in Patients With Helicobacter Pylori Infection.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 23 Feb 2012

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Finafloxacin (Primary) ; Amoxicillin; Esomeprazole
  • Indications Dyspepsia; Helicobacter pylori infections
  • Focus Therapeutic Use
  • Acronyms FLASH
  • Sponsors MerLion Pharmaceuticals

Most Recent Events

  • 17 Jun 2009 Actual end date (Apr 2009) added as reported by ClinicalTrials.gov.
  • 17 Jun 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
  • 01 Oct 2008 Planned end date changed from 1 Dec 2008 to 1 Nov 2008 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top